News for PHARM Stock

Pharming Group to participate in August investor conference Pharming Group reports second quarter and first half 2025 financial results and provides business update Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31 Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders Pharming Group to participate in June investor conferences Pharming Group reports first quarter 2025 financial results and provides business update Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) Pharming Group to report first quarter 2025 financial results on May 8 Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS Pharming Group announces the filing of its 2024 Annual Report and Form 20-F Pharming Group to participate in April investor conferences Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation Pharming Group reports fourth quarter and full year 2024 financial results and provides business update Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders Pharming Group to participate in March investor conference Pharming Group to report fourth quarter and full year 2024 financial results on March 13 Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent Pharming Group to participate in February investor conference Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period Pharming Group to convene Extraordinary General Meeting of Shareholders Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer Pharming announces public cash offer to the shareholders of Abliva AB Pharming announces positive topline data in pediatric clinical trial of leniolisib Pharming Group to participate in November investor conference Pharming Group reports third quarter 2024 financial results and provides business update Pharming Group to report third quarter 2024 financial results on October 24 Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) Pharming Group to participate in September investor conferences Pharming Group reports second quarter and first half 2024 financial results and provides business update Pharming Group to report second quarter and first half 2024 financial results on August 1 Pharming Group to participate in June investor conferences Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders Pharming Group to participate in May investor conference Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 Pharming Group reports first quarter 2024 financial results and provides business update Pharming Group to report first quarter 2024 financial results on May 8 Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 Pharming Group announces the placement of €100 million convertible bonds due 2029 Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 Pharming announces completion of enrollment in pediatric clinical trial of leniolisib Pharming Group announces the 2024 Annual General Meeting of Shareholders Pharming Group announces the filing of its 2023 Annual Report and Form 20-F Pharming Group to participate in April investor conferences Pharming Group reports fourth quarter and full year 2023 financial results Pharming Group to report fourth quarter and full year 2023 financial results on March 14 Pharming Group to participate in February investor conferences Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval Pharming Group to participate in November investor conferences Pharming Group reports third quarter 2023 financial results Pharming Group to report third quarter 2023 financial results on October 26 Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders